Bellevue Group Ag Akero Therapeutics, Inc. Transaction History

Bellevue Group Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$41.19 - $52.25 $86,499 - $109,725	-2,100 Reduced 7.75%	25,000 $1.26 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $36,890 - $56,880	1,000 Added 3.83%	27,100 $1.27 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $616,818 - $831,472	-16,550 Reduced 38.8%	26,100 $998,000
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $33,975 - $55,676	1,016 Added 2.44%	42,650 $2.34 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $422,585 - $1.42 Million	41,634 New	41,634 $1.42 Million

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.45B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.